Scotiabank Forecasts Albemarle’s FY2026 Earnings (NYSE:ALB)

Albemarle Corporation (NYSE:ALB) – Scotiabank reduced their FY2026 EPS estimates for shares of Albemarle in a research report issued to clients and investors on Tuesday, February 17th. Scotiabank analyst B. Isaacson now anticipates that the specialty chemicals company will post earnings per share of $8.38 for the year, down from their previous estimate of $9.57. Scotiabank currently has a “Sector Outperform” rating and a $200.00 target price on the stock. The consensus estimate for Albemarle’s current full-year earnings is ($0.04) per share. Scotiabank also issued estimates for Albemarle’s FY2027 earnings at $9.96 EPS.

Albemarle (NYSE:ALB) last released its earnings results on Wednesday, February 11th. The specialty chemicals company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.13). The firm had revenue of $1.43 billion during the quarter, compared to the consensus estimate of $1.34 billion. Albemarle had a negative net margin of 10.74% and a positive return on equity of 0.41%. The firm’s revenue was up 15.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.09) EPS.

Other equities analysts have also recently issued reports about the company. Royal Bank Of Canada boosted their target price on Albemarle from $200.00 to $216.00 and gave the company an “outperform” rating in a research note on Tuesday. BMO Capital Markets upped their price objective on Albemarle from $145.00 to $210.00 and gave the company an “outperform” rating in a research report on Tuesday, January 20th. JPMorgan Chase & Co. reduced their target price on Albemarle from $195.00 to $145.00 and set a “neutral” rating for the company in a report on Friday, February 13th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Albemarle in a report on Monday, December 29th. Finally, Jefferies Financial Group boosted their target price on Albemarle from $210.00 to $230.00 and gave the stock a “buy” rating in a research report on Wednesday, January 28th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $167.52.

Albemarle Stock Down 1.7%

Shares of NYSE:ALB opened at $168.32 on Thursday. The company has a current ratio of 2.23, a quick ratio of 1.57 and a debt-to-equity ratio of 0.41. Albemarle has a 12-month low of $49.43 and a 12-month high of $195.68. The stock’s 50-day moving average price is $161.16 and its 200-day moving average price is $117.79. The stock has a market capitalization of $19.84 billion, a P/E ratio of -29.27, a price-to-earnings-growth ratio of 1.79 and a beta of 1.44.

Institutional Trading of Albemarle

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its holdings in Albemarle by 2.0% in the 2nd quarter. Geode Capital Management LLC now owns 2,954,331 shares of the specialty chemicals company’s stock worth $184,782,000 after buying an additional 59,104 shares during the period. ProShare Advisors LLC boosted its stake in shares of Albemarle by 48.5% in the second quarter. ProShare Advisors LLC now owns 2,870,110 shares of the specialty chemicals company’s stock worth $179,870,000 after acquiring an additional 937,538 shares during the period. Earnest Partners LLC grew its position in shares of Albemarle by 14.6% during the fourth quarter. Earnest Partners LLC now owns 1,630,394 shares of the specialty chemicals company’s stock worth $230,603,000 after purchasing an additional 207,770 shares in the last quarter. Manning & Napier Advisors LLC bought a new stake in Albemarle during the 3rd quarter valued at approximately $138,723,000. Finally, Dimensional Fund Advisors LP lifted its holdings in Albemarle by 3.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,475,832 shares of the specialty chemicals company’s stock worth $119,710,000 after purchasing an additional 52,698 shares in the last quarter. 92.87% of the stock is owned by hedge funds and other institutional investors.

Albemarle Company Profile

Albemarle Corporation is a leading global specialty chemicals company primarily engaged in the production and distribution of lithium, bromine, and catalysts. Its lithium segment supplies key components used in rechargeable batteries for electric vehicles, portable electronics, and grid storage systems. The company’s bromine specialty products serve a wide range of industries, including oil and gas drilling fluids, fire safety solutions, and water treatment. In its catalysts division, Albemarle provides products for petroleum refining, chemical processing and emissions control.

Founded in 1994 as a spin-off from Ethyl Corporation, Albemarle has grown through strategic acquisitions and capacity expansions to become one of the world’s foremost chemical producers.